Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Spironolactone in Hemodialysis Patients With Resistant Hypertension
NCT07888504Phase 4Completed
- Sponsor
- Universitas Sebelas Maret
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of spironolactone in resistant hypertension (RH), sponsored by Universitas Sebelas Maret. Primary endpoints: Systolic Blood Pressure at 6 weeks and Diastolic Blood Pressure at 6 weeks. Started Aug 2024; status: completed.
02
Drugs
spironolactone
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT07888504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07888504.